EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma

Renata Ferrarotto iD, Luana G Sousa iD, Lei Feng, Frank Mott iD, George Blumenschein, Mehmet Altan, Diana Bell, Flavia Bonini, Kaiyi Li, Mario L Marques-Piubelli iD, Eduardo A Dal Lago, Jason J Johnson iD und 8 weitere

Journal of Clinical Oncology · 20.05.2023 · 41 (15) · 2843-2851

DOI: 10.1200/jco.22.02221 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.05.2023. Verfasst von Renata Ferrarotto und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Carcinoma, Adenoid Cystic. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIDCR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE We conducted a phase II trial evaluating the efficacy of VEGFR inhibitor axitinib and PD-L1 inhibitor avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC). PATIENTS AND METHODS Eligible patients had R/M ACC with progression within 6 months before enrollment. Treatment consisted of axitinib and avelumab. The primary end point was objective response rate (ORR) per RECIST 1.1; secondary end points included progression-free survival (PFS), overall survival (OS), and toxicity. Simon's optimal two-stage design tested the null hypothesis of ORR ≤5% versus ORR ≥20% at 6 months; ≥4 responses in 29 patients would reject the null hypothesis. RESULTS Forty patients enrolled from July 2019 to June 2021; 28 were evaluable for efficacy (six screen failures; six evaluable for safety only). The confirmed ORR was 18% (95% CI, 6.1 to 36.9); there was one unconfirmed partial response (PR). Two patients achieved PR after 6 months; thus, the ORR at 6 months was 14%. The median follow-up time for surviving patients was 22 months (95% CI, 16.6 to 39.1 months). The median PFS was 7.3 months (95% CI, 3.7 to 11.2 months), 6-month PFS rate was 57% (95% CI, 41 to 78), and median OS was 16.6 months (95% CI, 12.4 to not reached months). Most common treatment-related adverse events (TRAEs) included fatigue (62%), hypertension (32%), and diarrhea (32%). Ten (29%) patients had serious TRAEs, all grade 3; four patients (12%) discontinued avelumab, and nine patients (26%) underwent axitinib dose reduction. CONCLUSION The study reached its primary end point with ≥4 PRs in 28 evaluable patients (confirmed ORR of 18%). The potential added benefit of avelumab to axitinib in ACC requires further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Adenoid CysticHumansAxitinibAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Substanzen

AxitinibavelumabAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Pathology, City of Hope, Duarte, CA.
  • Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.

ORCID-Profile: Renata Ferrarotto, Luana G Sousa, Frank Mott, Mario L Marques-Piubelli, Jason J Johnson, Yoshitsugu Mitani, Anna Lee, Yasir Elamin

Förderung

  • NCI NIH HHS
  • NIDCR NIH HHS

Zitieren

APA

Ferrarotto, R., Sousa, L. G., Feng, L., Mott, F., Blumenschein, G., Altan, M., Bell, D., Bonini, F., Li, K., Marques-Piubelli, M. L., Dal Lago, E. A., Johnson, J. J., Mitani, Y., Godoy, M., Lee, A., Kupferman, M., Hanna, E., Glisson, B. S., Elamin, Y., & El-Naggar, A. (2023). Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. Journal of Clinical Oncology, 41(15), 2843-2851. https://doi.org/10.1200/jco.22.02221

Vancouver

Ferrarotto R, Sousa LG, Feng L, Mott F, Blumenschein G, Altan M, et al. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. Journal of Clinical Oncology. 2023;41(15):2843-2851. doi:10.1200/jco.22.02221

BibTeX
@article{Ferrarotto2023,
  author = {Ferrarotto, Renata and Sousa, Luana G and Feng, Lei and Mott, Frank and Blumenschein, George and Altan, Mehmet and Bell, Diana and Bonini, Flavia and Li, Kaiyi and Marques-Piubelli, Mario L and Dal Lago, Eduardo A and Johnson, Jason J and Mitani, Yoshitsugu and Godoy, Myrna and Lee, Anna and Kupferman, Michael and Hanna, Ehab and Glisson, Bonnie S and Elamin, Yasir and El-Naggar, Adel},
  title = {Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {15},
  pages = {2843--2851},
  doi = {10.1200/jco.22.02221}
}
Kostenlos starten →